Xanodyne Pharmaceuticals Inc. which makes Darvon and Darvocet, the brand version of the painkiller propoxyphene, has agreed to withdraw the medication from the U.S. market at the request of the U.S. Food Administration. The FDA has also informed generic manufacturers of Xanodyne’s decision and they will be removing their propoxyphene-containing products from the market as well.
Category Archives: Drug Safety Information Podcasts
FDA approves Xgeva to help prevent cancer-related bone injury
Xgeva, cancer
FDA Warning Letters issued to four makers of caffeinated alcoholic beverages
The U.S. Food and Drug Administration today warned four companies that the caffeine added to their malt alcoholic beverages is an “unsafe food additive” and said that further action, including seizure of their products, is possible under federal law. (DSK)
FDA approves new treatment option for late-stage breast cancer
Halaven, metastatic breast cancer
FDA launches initiative to develop innovative external defibrillators
Safety concerns on the devices that treat abnormal heart rhythms also to be addressed. The U.S. Food and Drug Administration today announced a program aimed at facilitating the development of safer, more effective external defibrillators used to treat abnormal heart rhythms through improved design and manufacturing practices.
FDA Urges Consumers to be ‘Smart’ about Antibiotic Use
This year, millions of antibiotics will be prescribed. Antibiotics can be used to treat bacterial infections; however, they are commonly over-prescribed. Patients sometimes ask their health care professional to prescribe antibiotic drugs for viral infections, like the common cold, despite the fact that they will not work and may lead to potentially harmful side effects. The misuse of antibiotics has contributed to one of the world’s most pressing public health problems today, antibiotic resistance.
FDA Approves Egrifta to Treat Lipodystrophy in HIV Patients
lipodystrophy
Pharmaceutical Company Lawyer Charged with Obstruction and Making False Statements
Pharmaceutical Company Lawyer Charged with Obstruction and Making False Statements
Drug Safety Podcasts for Healthcare Professionals: Ongoing Safety Review of GnRH Agonists and possible increased risk of diabetes and certain cardiovascular diseases
On May 3rd, 2010, FDA announced that the agency is evaluating whether GnRH Agonists may increase the risk of diabetes and certain cardiovascular diseases (heart attack, sudden cardiac death, stroke) in men receiving these medications for the treatment of prostate cancer.
Drug Safety Podcasts for Healthcare Professionals: New Boxed Warning on severe liver injury with propylthiouracil
FDA has now added a Boxed Warning to the label for propylthiouracil, a drug used to treat hyperthyroidism, to include information about reports of severe liver injury and acute liver failure, some of which have been fatal, in adult and pediatric patients using this medication.